SUMMARY BACKGROUND DATA: The intestine has been more difficult to transplant than other solid organs. We analyzed registry data to determine the scope and success of intestine transplantation in the current era. METHODS: All known intestinal-transplant programs participated. Patient- and graft-survival estimates were obtained using the Kaplan-Meier product limit method and were analyzed with the Wilcoxon statistic. RESULTS: Sixty-one programs provided data on 989 grafts in 923 patients. Four patients were lost to follow-up. The short-gut syndrome was the most common primary indication for transplantation. Sixty-one percent of the recipients were < or =18 years. Proportionally more combined intestinal and liver transplants were performed in this group. More than 80% of all current survivors had stopped parenteral nutrition and resumed normal daily activities. A multivariate analysis of cases within the last 5 years revealed that transplantation of patients waiting at home, recipient age, antibody induction immune suppression, and center experience with at least 10 cases were associated with improved patient survival. One-year graft survival rates of 81% were achieved in patients who were induced with antithymocyte globulin and maintained on tacrolimus. CONCLUSIONS: Transplantation is an effective therapy for the treatment of patients with end-stage intestine failure who cannot tolerate parenteral nutrition. With newer immune suppressive protocols, 1-year graft and patient survival rates approach the results of liver transplantation. Further improvement in survival are expected with early referral since suitable donor organs are scarce and survival rates are better when patients are well enough to wait at home for their transplant.
SUMMARY BACKGROUND DATA: The intestine has been more difficult to transplant than other solid organs. We analyzed registry data to determine the scope and success of intestine transplantation in the current era. METHODS: All known intestinal-transplant programs participated. Patient- and graft-survival estimates were obtained using the Kaplan-Meier product limit method and were analyzed with the Wilcoxon statistic. RESULTS: Sixty-one programs provided data on 989 grafts in 923 patients. Four patients were lost to follow-up. The short-gut syndrome was the most common primary indication for transplantation. Sixty-one percent of the recipients were < or =18 years. Proportionally more combined intestinal and liver transplants were performed in this group. More than 80% of all current survivors had stopped parenteral nutrition and resumed normal daily activities. A multivariate analysis of cases within the last 5 years revealed that transplantation of patients waiting at home, recipient age, antibody induction immune suppression, and center experience with at least 10 cases were associated with improved patient survival. One-year graft survival rates of 81% were achieved in patients who were induced with antithymocyte globulin and maintained on tacrolimus. CONCLUSIONS: Transplantation is an effective therapy for the treatment of patients with end-stage intestine failure who cannot tolerate parenteral nutrition. With newer immune suppressive protocols, 1-year graft and patient survival rates approach the results of liver transplantation. Further improvement in survival are expected with early referral since suitable donor organs are scarce and survival rates are better when patients are well enough to wait at home for their transplant.
Authors: D G Farmer; S V McDiarmid; H Yersiz; G Cortina; J Vargas; A J Maxfield; B Vandenbogaart; M Correa; A Kroeber; S Geevarghese; R W Busuttil Journal: Transplant Proc Date: 2002-05 Impact factor: 1.066
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: K Abu-Elmagd; J Reyes; G Bond; G Mazariegos; T Wu; N Murase; R Sindhi; D Martin; J Colangelo; M Zak; D Janson; M Ezzelarab; I Dvorchik; M Parizhskaya; M Deutsch; A Demetris; J Fung; T E Starzl Journal: Ann Surg Date: 2001-09 Impact factor: 12.969
Authors: Thomas M Fishbein; Thomas Schiano; Neil LeLeiko; Marcelo Facciuto; Menahem Ben-Haim; Sukru Emre; Patricia A Sheiner; Myron E Schwartz; Charles M Miller Journal: J Gastrointest Surg Date: 2002 Jul-Aug Impact factor: 3.452
Authors: F M Ruemmele; F Sauvat; V Colomb; M Jugie; D Jan; D Canioni; D Damotte; S Sarnacki; N Brousse; Y Revillon; O Goulet Journal: Gut Date: 2006-06 Impact factor: 23.059
Authors: Alexander Copelan; Daniel George; Baljendra Kapoor; Hahn Vu Nghiem; Jonathan M Lorenz; Brian Erly; Weiping Wang Journal: Semin Intervent Radiol Date: 2015-06 Impact factor: 1.513